Sentien Biotechnologies Obtains Series A Funding

  • Feed Type
  • Date
  • Company Name
    Sentien Biotechnologies
  • Mailing Address
    196 Boston Avenue Medford, MA 02155 USA
  • Company Description
    Sentien has developed proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Sentien will use the proceeds of its Series A round to fund its activities through a planned Phase I study of their lead product, the Sentinel™, a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI).
  • M&A Terms
  • Venture Investor
    Boehringer Ingelheim Venture Fund
  • Venture Investor
    Portage Venture Partners

Trending on Xconomy